Dr. Lillian Siu is a senior medical oncologist at the Princess Margaret Cancer Centre and a Professor of Medicine at the University of Toronto. She is the Co-Principal Investigator of the OICR-supported Ontario-wide Cancer Targeted Nucleic Acid Evaluation (OCTANE) study. Dr. Siu is the Director of the Phase 1 Program and Co-Director of the Bras and Family Drug Development Program at the Princess Margaret Cancer Centre, holds the BMO Chair in Precision Cancer Genomics, and is the clinical lead for the Tumor Immunotherapy Program at the Princess Margaret Cancer Centre, where she has been leading genomics initiatives and immuno-oncology trials. Dr. Siu served on the Board of Directors for the American Society of Clinical Oncology (ASCO) for a four-year term (2012-2016). She also served as a member of the Nomination Committee for the AACR (2014-2016). She currently serves on the AACR Board of Directors for a three-year term (2017-2020).